Patient guide

CAR-T Therapy in China: A Practical Guide for International Patients

How CAR-T cell therapy works, how China regulates and delivers it, what the treatment journey looks like for patients travelling from abroad, and how a coordination team supports each step.

By Wenhao Zhu·Updated 2026-10-16·9 min read

Key facts

  • CAR-T therapy re-engineers a patient’s own T-cells to recognise cancer cells; every treatment course is manufactured individually for that patient.
  • In China, CAR-T products are regulated by the National Medical Products Administration (NMPA) and delivered at accredited Grade 3A hospitals, usually by haematology or oncology departments.
  • The laboratory manufacturing phase alone typically takes several weeks, so international patients should plan for a stay of a number of weeks in total.
  • The first practical step is a medical records review; whether CAR-T is appropriate is a clinical decision made only by the treating physicians.
  • There is no separate medical visa category: treatment trips use S2 (up to 180 days) or S1 (longer stays), supported by the hospital’s invitation letter.

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most discussed advances in modern cancer care. In recent years, China has become one of the countries where this therapy is most widely delivered, with products authorised by the national regulator and treatment programmes running at accredited tertiary hospitals.

This guide explains, in plain language, how CAR-T therapy works, how it is regulated in China, what the journey looks like for a patient travelling from abroad, and how a coordination team supports you at every step. It is compiled from public regulatory announcements and hospital information — it is not medical advice, and it does not promise any outcome.

What is CAR-T therapy?

CAR-T stands for "chimeric antigen receptor T-cell" therapy. It belongs to a category of treatment sometimes called cell therapy or immunotherapy. Instead of using drugs or radiation to attack cancer directly, CAR-T uses a patient's own immune cells, re-engineered in a laboratory to recognise and respond to the patient's cancer cells.

In simplified terms, the process has four stages: a sample of the patient's T-cells (a type of white blood cell) is collected; the cells are genetically engineered in a specialised laboratory so that they carry a receptor that targets the cancer; the engineered cells are grown in number; and they are infused back into the patient, where they continue to act against the disease.

Because each patient's cells are processed individually, CAR-T is not an off-the-shelf product. Every treatment course is personally manufactured, which is why the journey involves a dedicated laboratory phase and careful planning of timing.

How is CAR-T regulated in China?

CAR-T products in China are regulated by the National Medical Products Administration (NMPA). Since 2021, the NMPA has approved several CAR-T products developed by Chinese companies and joint ventures, and the list of authorised products and approved hospitals continues to grow.

Treatment is delivered at accredited tertiary (Grade 3A) hospitals, typically by haematology or oncology departments with dedicated cell-therapy experience. Manufacturing laboratories operate under national quality standards, and each step of the process — from cell collection to infusion — follows protocols defined by the regulator and the treating hospital.

Approved indications are defined in each product's labelling and generally cover certain blood cancers that have not responded to earlier lines of treatment. Whether a specific product or programme is appropriate for a specific patient is a medical determination made by the treating physicians — never a decision made by an intermediary or by the patient alone.

Who may be a candidate?

Eligibility for CAR-T therapy is a clinical judgement. In general terms, physicians consider patients whose diagnosis matches an approved indication and whose previous treatments have not achieved the desired result, but every case also depends on disease status, organ function, prior therapies and many other individual factors.

The practical first step is not a booking or a payment — it is a review of your medical records by the treating team. Physicians assess whether CAR-T therapy is medically appropriate, whether any alternative approaches should be considered first, and what preparatory examinations would be needed. Only after this review can anyone give you a realistic picture of timing, hospital options and cost.

This is the role a coordination team plays: we translate and organise your records, submit them to the relevant departments, and bring back a written medical opinion — so that the decision you make is based on facts, not on marketing.

The treatment journey for international patients

Every case is different, but the journey for a patient travelling from abroad usually follows the steps below. Your coordinator keeps you informed at each stage and translates between you and the medical team.

  1. Records review — you send your diagnosis reports, pathology results, imaging and treatment history; they are translated into a structured English (or Chinese) summary for the medical team.
  2. Remote consultation — physicians review the case and reply with a written opinion: whether CAR-T therapy is appropriate, what preparatory tests are needed, and a preliminary timeline.
  3. Admission and work-up — you travel to China; before treatment begins, the hospital repeats or completes key examinations (imaging, laboratory tests, and confirmation of diagnosis) to establish a current baseline.
  4. Cell collection — T-cells are collected from your blood through a process called apheresis, which usually takes a few hours.
  5. Manufacturing — the collected cells are engineered and multiplied in the laboratory. This phase typically takes several weeks, during which you may stay in China or, subject to the physicians' assessment, return home and come back.
  6. Bridging therapy — if the medical team recommends it, interim treatment is given to keep the disease controlled while your cells are being manufactured.
  7. Infusion and monitoring — before infusion, a short course of chemotherapy prepares your immune system. The engineered cells are then infused, and you stay hospitalised under close monitoring, as this phase requires careful observation by the treating team.
  8. Recovery and follow-up — after discharge, a follow-up plan is agreed. For international patients this usually combines check-ups in China with structured remote follow-up coordinated with physicians in your home country.

Understanding the cost structure

China Medical Care does not publish prices, and you should be cautious of anyone who quotes a fixed price for cell therapy before reviewing your case. CAR-T treatment costs vary between hospitals, between products and between patients, because each course is individually manufactured and hospitalised.

What we can tell you in advance is what the final cost is made of. A written, itemised estimate from the hospital typically covers: pre-treatment examinations and diagnostic work-up; the apheresis procedure; cell manufacturing and processing (usually the largest single component); bridging therapy, if required; the infusion procedure and inpatient monitoring period; medications during admission; and post-discharge follow-up visits.

Once the medical team has reviewed your case, your coordinator provides a written, itemised estimate from the hospital, so you can see exactly what each component costs before making any decision. If you use international insurance, we supply the documentation your insurer needs to assess coverage.

How China Medical Care helps

China Medical Care is a coordination service — we are not a hospital and we do not provide treatment. What we do is remove the practical barriers between you and the accredited hospitals in our network: organising and translating medical records, obtaining written medical opinions, matching your case with the right departments, providing itemised cost estimates, assisting with the hospital's invitation letter for your visa application, arranging interpreters and accommodation, and coordinating remote follow-up after you return home.

All information we provide about hospitals and therapies is compiled from public sources and from the clinical teams themselves, and it describes institutions and processes — never promised outcomes. Treatment decisions rest entirely with you and your physicians.

Frequently asked questions

Only the treating physicians can answer this after reviewing your full medical records. In general, CAR-T products approved in China are indicated for certain blood cancers that have not responded adequately to earlier treatments. Send us your diagnosis reports and treatment history — the medical team will give you a written opinion on whether CAR-T therapy is appropriate for your case.

The laboratory manufacturing phase alone usually takes several weeks, and you should also plan time for admission, work-up, infusion and monitored recovery. Many international patients plan to stay in China for a number of weeks in total. After your records are reviewed, the medical team can give you a case-specific timeline.

Yes. The follow-up plan is agreed at discharge and usually combines check-ups in China with structured remote follow-up. We coordinate with physicians in your home country and provide English-language medical documentation for them.

Diagnosis reports, pathology results, recent imaging (on disc or digital), a summary of previous treatments (chemotherapy, transplants, radiation), your current medication list, and identification documents. Your coordinator will give you a checklist and handle translation.

Costs depend on the hospital, the specific product and your case — so no responsible party quotes a fixed price before a medical review. After the physicians assess your records, we provide a written, itemised estimate from the hospital covering every component of the treatment.

There is no separate "medical" visa category. International patients coming to China for treatment apply under a private-affairs category — S2 for stays of up to 180 days, or S1 for longer stays — supported by the invitation letter issued by the treating hospital. Your coordinator assists with the documentation and the appointment process at the consulate. Allow enough lead time: start the records review before you begin the visa process, and note that the decision on the visa rests with the issuing authority.

Partner hospitals for this therapy

Learn more about our Precision medicine programme

Related guides

Sources

  1. Cell Therapy Products: Technical Guideline for Research and Evaluation (Trial) — NMPA Announcement No. 216 of 2017 — National Medical Products Administration (NMPA) · checked 2026-11-22
  2. Technical Guideline for Clinical Trials of Immune Cell Therapy Products (Trial) — CDE Announcement No. 14 of 2021 — Center for Drug Evaluation, National Medical Products Administration · checked 2026-11-22
  3. Visa Application Instructions of the People's Republic of China — private-affairs (S1/S2) visas — Ministry of Foreign Affairs of the PRC · checked 2026-11-22